EANS-News: Epigenomics Septin9 Biomarker detects Colon Cancer equally in both sides of the Colon

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

New Products/Company Information/molecular diagnostics

Berlin, Germany, and Seattle, WA, U.S.A., February 16, 2012 (euro
adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX), the
German-American cancer molecular diagnostics company, is pleased to
announce the results from a study conducted in collaboration with
Professor Dr. Béla Molnár and his team from the 2nd Department of
Internal Medicine of Semmelweis University in Budapest, Hungary. In
the study, the blood based detection of methylated Septin9 in
colorectal cancer (CRC) cases was assessed in the left and right side
of the colon.

In a blinded case control study of a total of 184 study participants,
plasma from 92 CRC cases (56 left-, 36 right-sided cases) was
analyzed and methylated Septin9 was detected in a total of 88 cancer
cases, representing 96% sensitivity for overall CRC detection at a
specificity of 85%. The control arm consisted of 92 samples of
individuals with no evidence of disease as verified by colonoscopy.
Sensitivity for detection of left- and right-sided cases was 96% and
94% respectively, thus showing no significant difference between
cancer detection in either side of the colon.

In a subset of 39 subjects that received a fecal occult blood test
(FOBT, Hemoccult II stool test) in addition to a Septin9 test, the
sensitivities for FOBT for the detection of 12 left- sided cases was
83% and 50% for the 10 right-sided cases in this study. Overall,
sensitivity for FOBT was 68% and specificity was 71%.

The complete data will be submitted by Prof. Molnár for publication
in a peer reviewed journal in due course.

Dr. Jürgen Beck, Senior Vice President of Medical Affairs commented:
"These results are in line with previously reported performance
evaluations for CRC detection in case control studies performed by
Epigenomics and other parties. They reflect the value and the
superiority of blood based testing of methylated Septin9 for early
detection of colorectal cancer, independently of the localization of
the cancerous lesion"

- Ends -

Further Information

Contact Epigenomics AG

Antje Zeise
Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer
earlier and more accurately, leading to improved outcomes for
patients. Epigenomics' lead product, Epi proColon®, is a blood-based
test for the early detection of colorectal cancer, which is currently
marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple
partnerships with leading global diagnostic companies including
Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an
international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain
forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and
does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States or Canada. The analytical and
clinical performance characteristics of any Epigenomics product based
on this technology which may be sold at some future time in the U.S.
have not been established.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English